Rifaximin fails to prevent campylobacteriosis in the human challenge model: a randomized, double-blind, placebo-controlled trial (Q46260190)

20 December 2017

title

Rifaximin fails to prevent campylobacteriosis in the human challenge model: a randomized, double-blind, placebo-controlled trial (English)

1 reference

20 December 2017

1 reference

16

Patricia Guerry

1 reference

20 December 2017

9

Frédéric Poly

1 reference

20 December 2017

3

David A Sack

1 reference

20 December 2017

4

Kawsar R Talaat

1 reference

20 December 2017

author name string

Joanna E Rimmer

1

1 reference

20 December 2017

Clayton Harro

2

1 reference

20 December 2017

Ramiro L Gutierrez

5

1 reference

20 December 2017

Barbara DeNearing

6

1 reference

20 December 2017

Jessica Brubaker

7

1 reference

20 December 2017

Renee M Laird

8

1 reference

20 December 2017

Alexander C Maue

10

1 reference

20 December 2017

Kayla Jaep

11

1 reference

20 December 2017

Ashley Alcala

12

1 reference

20 December 2017

Yelizaveta Mochalova

13

1 reference

20 December 2017

Christina L Gariepy

14

1 reference

20 December 2017

Subhra Chakraborty

15

1 reference

20 December 2017

David R Tribble

17

1 reference

20 December 2017

Chad K Porter

18

1 reference

20 December 2017

Mark S Riddle

19

1 reference

20 December 2017

language of work or name

English

0 references

publication date

14 November 2017

1 reference

20 December 2017

Clinical Infectious Diseases

published in

1 reference

20 December 2017

Foodborne illness acquired in the United States--major pathogens

cites work

1 reference

Global Epidemiology of Campylobacter Infection

21 January 2018

1 reference

Modelling study to estimate the health burden of foodborne diseases: cases, general practice consultations and hospitalisations in the UK, 2009.

21 January 2018

1 reference

Travelers' Diarrhea: An Update on the Incidence, Etiology, and Risk in Military Deployments and Similar Travel Populations

21 January 2018

1 reference

The chronic gastrointestinal consequences associated with campylobacter

21 January 2018

1 reference

Campylobacter reactive arthritis: a systematic review

21 January 2018

1 reference

Update on the burden of Campylobacter in developing countries

21 January 2018

1 reference

Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

21 January 2018

1 reference

Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea

21 January 2018

1 reference

Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico

21 January 2018

1 reference

Campylobacter jejuni strain CG8421: a refined model for the study of Campylobacteriosis and evaluation of Campylobacter vaccines in human subjects

21 January 2018

1 reference

Characterization of two Campylobacter jejuni strains for use in volunteer experimental-infection studies

21 January 2018

1 reference

Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge model

21 January 2018

1 reference

Recrudescent Campylobacter jejuni infection in an immunocompetent adult following experimental infection with a well-characterized organism

21 January 2018

1 reference

Caught in the act: in vivo development of macrolide resistance to Campylobacter jejuni infection

21 January 2018

1 reference

Differentiation of Campylobacter coli, Campylobacter jejuni, Campylobacter lari, and Campylobacter upsaliensis by a multiplex PCR developed from the nucleotide sequence of the lipid A gene lpxA.

21 January 2018

1 reference

Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans

21 January 2018

1 reference

Efficacy of rifaximin in prevention of travelers' diarrhea: a meta-analysis of randomized, double-blind, placebo-controlled trials

21 January 2018

1 reference

Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome

21 January 2018

1 reference

Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.

21 January 2018

1 reference

In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions

21 January 2018

1 reference

In vitro activity and fecal concentration of rifaximin after oral administration

21 January 2018

1 reference

Bile acids improve the antimicrobial effect of rifaximin

21 January 2018

1 reference

Campylobacter colitis: histological immunohistochemical and ultrastructural findings

21 January 2018

1 reference

Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study

21 January 2018

1 reference

Antibiotic resistance in Campylobacter: emergence, transmission and persistence

21 January 2018

1 reference

ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1093/CID/CIX1014

1 reference

20 December 2017

1 reference

20 December 2017